United Therapeutics to Repurchase $1 Billion in Stock Through Accelerated Share Repurchase Program

United Therapeutics Corporation has announced a $1 billion accelerated share repurchase program with Citibank to repurchase an aggregate $1 billion of UTHR common stock. The company will repurchase these shares under the $1 billion repurchase program authorized by its board of directors. The shares will be repurchased based on the average daily volume-weighted average price of UTHR common stock, with final settlement expected in Q4 2025.

United Therapeutics Corporation (UTHR) has announced a significant financial move by entering into two Accelerated Share Repurchase (ASR) agreements with Citibank, N.A. (Citi) to repurchase an aggregate $1 billion of UTHR common stock. This strategic decision reflects the company's confidence in its near-term prospects and its ability to generate sustained revenue and cash flow growth.

Under the terms of the ASR agreements, United Therapeutics will make an aggregate upfront payment of $1 billion to Citi on August 4, 2025. The shares will be repurchased based on the average daily volume-weighted average price of UTHR common stock, with final settlement expected in the fourth quarter of 2025 for the uncollared ASR agreement and the first quarter of 2026 for the collared ASR agreement.

Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics, stated, "These expeditious agreements reflect our confidence in the intrinsic value of our stock, our upcoming catalysts, and our ability to generate sustained revenue and cash flow growth. Our capital allocation philosophy provides us with the flexibility to both invest in our future growth while returning capital to our shareholders, and we remain committed to this balanced approach that will leave us with ample remaining capital on our balance sheet to fulfill our long-term goals."

The repurchase program is authorized by the company's board of directors and was previously announced on July 30, 2025. At the time of the announcement, United Therapeutics had approximately 45.2 million shares outstanding.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful.

References:
[1] https://www.stocktitan.net/news/UTHR/united-therapeutics-corporation-announces-1-billion-accelerated-tvkhomun9gyx.html
[2] https://seekingalpha.com/news/4475083-united-therapeutics-outlines-1b-share-repurchase-and-12-percent-revenue-growth-while